HEAD AND NECK SQUAMOUS CELL CARCINOMA

This study is for people with HPV-positive head and neck cancer who have had surgery. It tests whether a lower dose of radiation (with or without chemo) can reduce long-term side effects while still keeping the cancer from coming back. About 304 participants will receive a reduce…

This study tests a new drug called petosemtamab against standard treatments for people with advanced head and neck cancer that has spread or come back. About 600 adults whose cancer worsened after standard therapies will be randomly assigned to receive either petosemtamab or anot…

This early-phase trial tests a new treatment called VET3-TGI, a virus designed to infect and kill cancer cells. It is given alone or with an immunotherapy drug (atezolizumab) to about 60 adults with advanced solid tumors that have not responded to standard treatments. The main go…

This early-phase study tests a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and understand side effects. About 493 adults with certain cancers like colorectal, lung, or pancre…

This early-stage study tests a new drug called CTX-8371 in people with advanced cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 adults with certain types of lung, breast, lymphoma, head and neck,…

This study compares two treatments for people with stage III-IVA head and neck cancer who have already had surgery to remove their tumor. One group gets radiation therapy alone, and the other gets radiation plus the chemotherapy drug cisplatin. The goal is to see which approach b…

This study tests an experimental drug called VMD-928, taken as a pill, either alone or with another drug (pembrolizumab), in people with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find a safe dose and see if it can shrink…

This study tests a program called ENDURE that helps head and neck cancer patients start radiation therapy within 6 weeks after surgery, as guidelines recommend. About 532 adults with certain types of head and neck cancer will take part. The program uses patient navigators to guid…

This study tests a new drug called ALE.P02 in people with advanced or spreading squamous cell cancers of the lung, head and neck, cervix, or esophagus. The drug is designed to find and attack cancer cells that have a specific protein (Claudin-1). The main goals are to check the d…

This early-stage study tests a new drug called IDE034 in about 150 adults with advanced solid tumors (like lung, ovarian, or colon cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink …

This study tests a new combination therapy for people with advanced head and neck cancer caused by HPV. The treatment includes a DNA vaccine (GX-188E), an immune booster (GX-I7), and an immunotherapy drug (nivolumab). The goal is to see if this combination can shrink tumors and h…

This study tests whether giving two drugs (pembrolizumab and IO102-103) before surgery is safe and effective for people with head and neck cancer. About 30 adults with removable tumors will receive the drug combination, then have surgery. Researchers will monitor side effects and…

This study is for people with advanced head and neck cancer that has come back or spread. It tests a special device placed directly into the tumor that gives off a unique type of radiation (alpha rays) combined with an immunotherapy drug called pembrolizumab. The goal is to see i…

This study tests a new treatment for a type of head and neck cancer that is hard to cure. It combines an experimental vaccine that targets a protein called IMP3 with an immunotherapy drug. The goal is to shrink tumors before surgery and prevent them from coming back after. The tr…

This study tests two experimental drugs, SYS6010 and Enlonstobart, together in people with head and neck cancer that has come back or spread. The goal is to see if the combination can shrink tumors and control the disease. About 70 adults who have not had prior systemic treatment…

This study is testing a new approach for people with certain head and neck cancers: using lower doses of radiation and chemotherapy, followed by surgery to remove any remaining cancer in the neck. The goal is to see if this gentler treatment can still control the cancer while red…

This study is for people with head and neck cancer that has come back or spread. It tests whether the drug cetuximab, given alone, can shrink tumors or slow the disease in patients who no longer benefit from immunotherapy. About 38 adults will take part, and the main goal is to s…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 uses the patient's own T cells, which are modified in…

This study tests a new combination of drugs and radiation for people whose head and neck cancer has returned after previous treatment. The goal is to find the safest dose and see how well the treatment works. About 30 participants will receive the drugs tislelizumab and pamiparib…

This study tests whether adding two immunotherapy drugs (cemiplimab and cetuximab) to standard chemotherapy before surgery is safe and effective for people with advanced head and neck cancer. The goal is to see if this combination can help patients avoid needing radiation therapy…

This early-phase study tests a new drug called AZD6750, which is designed to guide the immune system to attack cancer cells. It is for adults with advanced solid tumors like melanoma, lung cancer, or breast cancer that have not responded to other treatments. The study will check …

This early-phase study tests a new investigational drug called azirkitug, alone or combined with other drugs, in adults with advanced solid tumors such as lung, head/neck, colorectal, and breast cancers. The main goals are to check safety, side effects, and how the drug moves thr…

This study tests a new drug called CUE-101, alone or with pembrolizumab, in 30 people with newly diagnosed, advanced HPV-16 head and neck cancer that cannot be removed surgically. The goal is to see if these treatments can boost the immune system to fight the cancer before standa…

This early-phase study tests a new drug, CLSP-1025, designed to direct immune cells to attack tumors that have a specific p53 R175H mutation. The trial enrolls adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have worsened after standard treatments.…

This early-phase study tests a new drug, ONM-501, injected directly into tumors, either alone or with another drug (cemiplimab), in people with advanced solid tumors or lymphomas that have not responded to other treatments. The main goals are to find the safest dose and understan…

This study tests whether giving two immunotherapy drugs (cemiplimab and CDX-1140) before surgery works better than one drug alone for people with stage III-IV head and neck cancer. About 44 participants will receive either the combo or just cemiplimab before their tumor is remove…

This study tests whether a blood test that tracks tumor DNA can help doctors decide when to add short bursts of chemotherapy to standard immunotherapy for people with recurrent or metastatic head and neck cancer. About 30 adults will receive pembrolizumab (immunotherapy) plus occ…

This study tests whether adding low-dose radiation to standard targeted therapy and immunotherapy before surgery helps shrink head and neck tumors more effectively than the drugs alone. About 98 adults with operable head and neck squamous cell carcinoma will be randomly assigned …

This study tests whether adding the experimental drug petosemtamab to the standard immunotherapy pembrolizumab helps people with advanced head and neck cancer live longer or shrink their tumors. About 700 adults whose cancer has spread or returned and whose tumors have a specific…

This early-stage trial tests a new radioactive drug, [225Ac]-FPI-2068, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see how the drug spreads in the body. About 70 people with cancers like lung, colon, …

This early-phase study is testing an experimental drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 96 …

This study tests a new experimental drug called GI-101, given alone or with other cancer drugs (pembrolizumab or lenvatinib), in people with advanced solid tumors that have spread. The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults with canc…

This study tests a new drug called SIM0610 in adults with advanced solid tumors (cancers that have spread). The main goals are to check safety and find the right dose. About 260 people with certain cancers like lung, colon, head and neck, or liver cancer can join. The study has t…

This study tests two experimental drugs, BL-B01D1 and SI-B003, given alone or together in people with head and neck cancer that has come back or spread. The goal is to see if these treatments can shrink tumors or slow the disease. About 186 adults aged 18 to 75 who have already t…

This study tests whether a drug called methylnaltrexone, usually used for constipation, can be safely given to people with oral cavity cancer for two weeks before their surgery. The goal is to check for side effects and see if it's safe. About 25 adults with resectable head and n…

This study tests an experimental oral drug called NEO212 in adults with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it can slow tumor growth. About 134 participants will receive NEO212 a…

This early-phase study tests a new drug, KIVU-107, in about 76 adults with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells. The main goal is to find the…

This early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head/neck cancer. The main goal is to check safety and find the best dose. Participants receive the drug and are monitored for side effects a…

This study tests whether combining three treatments—modified natural killer cells (PD-L1 t-haNK), an immune-boosting protein (Anktiva), and a targeted antibody (cetuximab)—can shrink tumors in people with advanced head and neck cancer that has come back or spread. About 25 adults…

This early-stage study tests an experimental drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The drug works by boosting the immune system to fight tumors. The main goals are to check safety and find the right dose, with a later …

This early-phase study tests a new radioactive drug (lutetium [177Lu]-BL-ARC001) in 22 adults with advanced lung, breast, head/neck, or other solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug s…

This study tests a new drug called SIBP-03 combined with cetuximab in people with advanced head and neck cancer that has come back or spread. It is for patients who have already tried immunotherapy and chemotherapy without success. The goal is to see if the combination can shrink…

This study tests an experimental pill, VLS-1488, in people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a protein that helps cancer cells divide. The trial has two parts: first finding a safe dose, then checking if it shrinks …

This study tests a new drug called volrustomig, either alone or with chemotherapy, in people with advanced or spreading solid tumors (cervical, head and neck, esophageal, or mesothelioma). The goal is to see if the drug can shrink tumors and control the disease. About 257 adults …

This study tests whether giving two drugs (cetuximab and cemiplimab) before surgery can help shrink head and neck squamous cell carcinoma. About 21 adults will receive the combination, then have surgery to remove their cancer. The main goal is to see how many patients have a majo…

This study tests a new combination of drugs (SI-B001 and SI-B003) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if this combination can shrink tumors and delay cancer growth. About 60 adults aged 18 to…

This study tests a new oral drug, IPN01194, in adults with advanced solid tumors (melanoma, colorectal, pancreatic, or head and neck cancers) that have not responded to standard treatments. The goal is to find the right dose and check if the drug is safe and can shrink tumors. Ab…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer and other solid tumors that have spread or cannot be removed. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 470 adults will take part.

This early-stage trial tests a new combination treatment for people with advanced HER2-positive solid tumors (like breast, lung, or stomach cancer). Participants receive an injection of a special virus directly into one tumor to activate the immune system, followed by an infusion…

This study tests whether adding an experimental drug (GB1211) to a standard immunotherapy (pembrolizumab) works better than the immunotherapy alone for people with advanced melanoma or head and neck cancer. About 92 adults whose cancer has spread or cannot be removed will take pa…

This study tests a new drug called TER-2013 in people with advanced solid tumors (like breast, endometrial, ovarian, lung, head and neck, esophageal, or cervical cancer) that have specific changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and shrinks tu…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…

This early-stage study tests a new treatment called MQ710, made from a modified virus, for people with advanced solid tumors that have not responded to standard therapies. The treatment is injected directly into tumors, either alone or with the immunotherapy drug pembrolizumab. T…

This early-stage study tests a new drug called CHS-114 in people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein on certain immune cells to help the body fight cancer. About 87 participants will receive the drug alone or …

This early-phase study tests a new drug called BL-M24D1 in 16 people with advanced head and neck cancer or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must be 18 or older and have t…

This early-phase trial tests a new drug called ZM008, alone and with another drug (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 100 adults with canc…

This study tests a new drug called LY4052031 in people with advanced or spreading solid tumors, including bladder, breast, lung, and other cancers. The goal is to see if the drug is safe and works against these cancers. About 420 participants will take part, and the study will la…

This study tests a combination of two drugs, ACR-368 and low-dose gemcitabine, in people whose head and neck cancer has come back or spread. The goal is to see if the treatment can shrink tumors and slow the disease. About 43 participants will receive the drugs every two weeks as…

This early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 166…

This early-stage study tests a new cancer treatment called FT836, a ready-made immune cell therapy, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers. The treatment is given alone or with chemotherapy and/or antibod…

This early-stage trial tests whether combining two imaging techniques can help surgeons better detect and remove head and neck cancer. About 40 adults with squamous cell carcinoma will receive a radioactive tracer before surgery and a fluorescent dye during surgery to highlight c…

This study tests a special dye called pegsitacianine that makes cancer cells glow during surgery. The goal is to help surgeons see and remove all cancer tissue in people with head and neck cancer, especially when the original tumor location is unknown. About 120 adults will recei…

This early-stage trial tests a radioactive drug called 111In-panitumumab to see if it can better find cancer that has spread to lymph nodes in people with head and neck cancer. About 30 patients scheduled for surgery will receive the drug and then get a special scan (SPECT/CT) to…

This early-phase study tests a new radioactive tracer called [18F]NOTA-ABY030, used with PET/CT scans, to see if it can safely and more accurately detect head and neck cancers that standard scans may miss. About 25 adults with squamous cell carcinoma of the head and neck will rec…

This study tests a new imaging drug called 89Zr panitumumab to see if it can more accurately find cancer that has spread in people with head and neck cancer. Standard PET/CT scans often miss or wrongly identify these spots. About 60 participants will receive the new imaging agent…

This early-phase study tests whether a protein called CFH, delivered through ice microneedles, can safely prevent radiation-induced skin fibrosis (hardening and scarring) in people with head and neck cancer. Nine participants will receive the patch twice a week during their radia…

This study tests whether a heavy lifting strength training program can help head and neck cancer survivors regain muscle strength, reduce fatigue, and improve quality of life. About 60 adults who finished cancer treatment at least one year ago will be randomly assigned to either …

This study tests whether a shorter course of high-dose radiation (SBRT) can safely reduce symptoms in people with head and neck cancer that cannot be cured. About 108 adults whose cancer has returned or spread will receive either standard or shortened radiation. The goal is to se…

This study looks at whether adding olanzapine to usual care can help prevent severe appetite loss and weight loss in people with head and neck cancer who are getting chemoradiation. About 66 adults will take part. The goal is to see if this approach helps patients maintain their …

This study is testing a special nutrition supplement in 52 people with head and neck, lung, or rectal cancer who are receiving standard cancer treatments like chemotherapy or radiation. The goal is to see if the supplement can reduce serious side effects and help patients stay on…

This study tests if a high dose of gabapentin can help prevent the need for strong opioid painkillers in people with head and neck cancer who get mouth sores from chemotherapy and radiation. About 228 adults will be randomly assigned to receive gabapentin or a placebo during thei…

This study tests if adding BMX-001 to standard care can reduce severe mouth sores caused by chemoradiation in head and neck cancer patients. About 98 adults will receive either BMX-001 or a placebo alongside their usual treatment. The goal is to see if BMX-001 helps prevent painf…

This study tests whether giving radiation only to high-risk areas after head and neck cancer surgery can reduce side effects without raising the chance of cancer coming back. About 50 adults with certain head and neck cancers will receive a personalized radiation plan. The goal i…

This study tests whether adding a special heat treatment (water-filtered infrared-A, or wIRA) to standard palliative radiation can help shrink tumors and ease symptoms in people with advanced head, neck, or skin cancers that cannot be cured. About 60 adults will receive the combi…

This pilot study tests whether a buried fat flap (taken from the thigh) is safe and helpful for reducing neck problems like pain, stiffness, swelling, and trouble swallowing after head and neck cancer treatment. About 12 adults who need a second neck surgery after radiation will …

This study looks at whether a simple blood test can tell which throat cancer patients can safely skip radiation after surgery. About 61 people with HPV-related throat cancer will have their blood tested before and after surgery. If the test is negative after surgery, they won't g…

This study looks at whether miniature, lab-grown versions of a patient's tumor (called organoids) can accurately predict which cancer drugs will work best. Researchers will compare the organoid test results with how the patient actually responds to treatment. The goal is to see i…

This study is gathering blood and tissue samples from 500 people with advanced head and neck cancer to look for genetic markers (biomarkers) that might predict how well treatments work. Participants continue their usual care while providing samples over time. The goal is to bette…

This study follows 110 adults with head/neck, lung, or rectal cancer to track changes in their nutrition and body composition during standard treatment. Researchers measure daily food intake, muscle mass, and strength over time. The goal is to gather data that will help design a …

This study is for people with head and neck cancers who are getting radiation therapy. It uses special PET/CT scans to see how radiation affects the blood vessels in the neck. The goal is to learn if a newer scan method (F-18 NaF PET/CT) can detect these changes better than the s…

This study tests whether using virtual reality (VR) and 3D models before surgery helps surgeons better plan and perform operations for head and neck cancer. About 160 adults with head and neck cancer will take part. The goal is to see if this technology leads to fewer leftover ca…

This study follows 220 people with HPV-related throat cancer after treatment to see if two things can predict if the cancer returns: changes in certain genes (TRAF3 and CYLD) and levels of HPV DNA in the blood. Participants will give blood samples and have regular CT scans. The g…

This study looks at whether offering hearing tests close to home or online can help more head and neck cancer patients get their hearing checked during treatment. Chemotherapy and radiation can cause hearing loss, but many patients skip follow-up tests. The goal is to see if easi…

This early-phase study tests whether a new radioactive tracer can help doctors see tumors on PET/CT scans. About 32 adults with different solid tumors will receive a single injection of the tracer. The goal is to understand where the tracer goes in the body, how it is cleared, an…

This study compares a new type of PET scan using 89Zr panitumumab with the standard FDG-PET scan to see which one better shows the size and location of head and neck cancers. About 14 newly diagnosed patients will get both scans before surgery. The results are for research only a…

This study uses repeated MRI scans during radiation therapy to see how head and neck tumors change. Researchers hope to learn which tumor areas need higher radiation doses. About 173 people with newly diagnosed head and neck cancer will participate, along with 20 healthy voluntee…